NRIX nurixtx.com: Enterprise Value to EBITDA Ratio

Nurix Therapeutics (NRIX) is recognized as one of the pioneers in targeted protein degradation, enjoying immense trust from global pharma behemoths. The business valuation via EV/EBITDA dynamics demonstrates a pricing trend where the value of 2.32 serves as the current metric. The model scales through partner royalties despite high research costs, while streamlined reagent delivery ensures the uninterrupted development of targeted drugs.

NRIX (Nurix Therapeutics Inc) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/14/2026

Comprehensive metric breakdowns and analytics for nurixtx.com (NRIX)

- stock price and consensus target price:

Stock Quotes Nurix Pharma|NRIX - Average Forecast Price

- company stock capitalization data:

Market Valuation Nurix Corp|NRIX - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share Nurix Therapeutics|NRIX - Total Net Assets|Market Capitalization to Book Value Ratio nurixtx.com|NRIX - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

NRIX - Company Net Income|Projected Future Earnings Nurix Therapeutics|NRIX - Price to Earnings Multiple|Projected Price to Earnings Nurix Therapeutics|NRIX - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Nurix Corp|NRIX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Nurix Therapeutics|NRIX - Earnings per share for the trailing year|Quarterly EPS earnings growth nurixtx.com|NRIX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Nurix Therapeutics

- issuer revenue and sales details:

NRIX - Company Sales Revenue|Projected Sales Volume Nurix Pharma|NRIX - P/S Multiple|Price-to-Projected Revenue Ratio Nurix Corp

Basic company analysis:Nurix Pharma NRIX

The long-term sustainability of Nurix Therapeutics (NRIX) is determined by its ability to generate value relative to the total enterprise value of the business, including debt. By analyzing fluctuations in the company's EV/EBITDA ratio, an investor assesses the efficiency of the operating cash flow before taxes and amortization, which in the biotechnology sector reflects speculative appetite for risk assets rather than a market cycle, amid stable demand for oncology therapies.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|ORIC (ORIC Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Relay Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tyra Biosciences, Inc. (TYRA)|VSTM (verastem.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GLUE (Monte Rosa Therapeutics, Inc.)|Enterprise Value to EBITDA Multiple Cullinan Oncology|Immuneering Inc. - EV/EBITDA Multiple|Company Value to EBITDA C4 Therapeutics Corp|BDTX (Black Diamond) - Enterprise Value to EBITDA Ratio|RPTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (PMV Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple